Articles tagged with Drug Discovery
In a new study, Northwestern scientists identified a previously unknown toxic sub-species of amyloid beta oligomers that drive brain changes in Alzheimer's disease. NU-9 decreased this toxin and reduced damage in a mouse model, suggesting it could prevent or delay the cascade of toxic events that destroy neurons.
A blood test may help doctors identify which patients with colon cancer can benefit from anti-inflammatory medication and chemotherapy after surgery. The test measures circulating tumor DNA levels, and high-risk patients who test positive see improved survival rates when taking celecoxib with chemotherapy.
Researchers developed a novel magnetic biosensing technique using polydopamine-coated magnetoliposomes to monitor lectin-glycan binding. The technique provides insight into the dynamics of sugar-protein interactions and holds promise for medical diagnostics, glycoscience research, and drug discovery.
A SickKids-led study reveals how bile acids can bind to block C. diff's most dangerous toxin, leading to the development of a new compound that neutralizes the toxin directly in the gut. This approach preserves gut health and targets the toxin with precision, offering hope for safer treatments.
The Jackson Laboratory's CARDIOVERSE project uses AI, stem cells, and genetic variation to predict drug safety before human trials. The initiative aims to reduce cardiotoxicity and improve patient stratification in clinical trials.
Researchers at Martin Luther University Halle-Wittenberg have developed a promising new substance that inhibits the ability of tuberculosis bacteria to produce energy and causes them to die. The compound, PRP020, targets the pathogen's ATP synthase but attacks a different site than existing drugs like bedaquiline.
Intellicule will utilize state-of-the-art deep-learning techniques to expand structural modeling and analysis for cryo-EM data. The company aims to overcome current limitations in biomolecular modeling, enabling the detection of atoms in low-resolution images.
Insilico Medicine will demonstrate how generative AI is accelerating therapeutic discovery, improving drug efficacy, and advancing personalized medicine. The company's pharma superintelligence platform aims to tackle challenging problems in modern science and medicine.
Biomedical researchers recommend diversifying funding sources, pursuing earlier licensing and commercialization, and fostering international collaborations. The US drug discovery landscape is at risk due to federal funding cuts, and alternative approaches are needed to ensure continued progress.
Researchers at the University of Virginia Health System have developed a new treatment for acute myeloid leukemia, a deadly form of blood cancer. The FDA-approved medication works by disrupting cellular protein interactions that drive leukemia cell growth and survival, offering patients a potential cure.
The article highlights the mismatch between psychedelics and economic drug development principles. Pharmaceutical companies are developing short-acting compounds and neuroplastogens to engineer trips out of the experience altogether. Dr. Sandy Hager's research suggests investors should remain cautious due to weak intellectual property ...
A new computational tool called DeepTarget predicts direct and indirect targets of cancer drugs, revealing that small molecules can have different targets and effects depending on the disease and cell type. The study demonstrates the tool's superior performance in real-world scenarios, highlighting its potential to accelerate drug deve...
Researchers identified TCF/LEF proteins as key regulators of the canonical Wnt pathway, which governs transcription in cancer and fibrotic diseases. The study reveals potential therapeutic targets for treating diverse diseases while avoiding toxicity associated with upstream Wnt inhibition.
Researchers found that selective enrichment of adhesion proteins like fibronectin and vitronectin maximizes optimal cell adhesion on plastic surfaces. The optimal UVO treatment time creates a mix of hydrophilic and hydrophobic regions, promoting attachment protein replacement and secure cell binding.
Researchers discover tiny antibody-like proteins from camels and llamas that can treat brain disorders like schizophrenia and Alzheimer’s disease with fewer side effects. The nanobodies are smaller than conventional antibodies, making them easier to produce and purify.
A new broad-spectrum antivenom developed by DTU researchers covers 17 African snake species and provides better protection against tissue damage, with a lower risk of immune reactions. The antivenom has shown impressive results in laboratory studies and could revolutionize the treatment of venomous snakebites in Africa.
The Mays Cancer Center stands among the nation's leading institutions recognized for excellence in cancer care and research. It is one of only four NCI-designated Cancer Centers in Texas, offering specialized programs and delivering comprehensive, multidisciplinary care supported by clinical research.
Researchers from The University of Osaka and The University of Tokyo have developed a novel technology that visualizes specific molecules inside living cells using light. The new photo-responsive alkyne tag enables precise visualization without disrupting molecular dynamics.
The FDA has approved elinzanetant for treating hot flashes and night sweats in postmenopausal women. The drug significantly reduces the frequency and severity of symptoms while improving sleep quality and quality of life.
Researchers at Sanford Burnham Prebys discovered a new mechanism to confer signaling bias in predictable ways, permitting rational design of new drugs. This breakthrough could lead to better therapies for addiction and psychiatric disorders by targeting the neurotensin receptor 1 (NTSR1) with biased modulators.
A new large language model, LassoESM, has been developed to predict lasso peptide properties, enabling the acceleration of rational design for biomedical applications. The model was trained on thousands of lasso peptide sequences and demonstrated accurate prediction of various properties.
Dr. Benjamin P. Brown proposes a targeted approach to improve the accuracy and speed of machine learning in drug discovery. His work focuses on creating a more generalizable deep learning framework for structure-based protein-ligand affinity ranking.
A team of UNLV researchers has engineered a new class of cannabidiol (CBD)-like medicines that show powerful seizure-reducing effects. The caraway-seed derived therapies offer a safer and more effective treatment for childhood seizure disorders than existing frontline therapies.
The Critical Path Institute has been recognized for its innovative approaches to regulatory science, which have measurably improved public health. The organization's work in creating practical tools and cross-sector collaborations has shortened drug development timelines and improved regulatory decisions.
The study identified chemical compounds that precisely block the interaction between RAS and a key pathway for tumour growth. The treatment has entered its first clinical trial in humans and has shown promising results, with potential to treat many different types of cancers while avoiding effects on healthy cells.
Researchers at the University of Bath develop a peptide fragment that locks alpha-synuclein into its healthy shape, blocking toxic clumps that cause nerve cell death. The breakthrough demonstrates the potential of rational peptide design to transform large proteins into compact drug-like molecules.
Pharma.AI is a comprehensive generative AI-powered drug discovery platform featuring PandaOmics, Generative Biologics, Chemistry42, Science42: DORA, and PreciousGPT. These platforms enhance target and biomarker discovery, biologics engineering, small molecule design, scientific research, and disease modelling.
Researchers identified citronellyl butyrate and other compounds with high binding affinity to DPP-4, suggesting strong inhibitory potential. The compounds' favorable pharmacokinetic properties, such as high absorption and blood-brain barrier permeability, make them promising candidates for antidiabetic treatments.
Researchers identify three primary UPR pathways and their downstream cascades, which play a crucial role in the differentiation of osteoblasts and osteoclasts. Targeting these pathways with emerging drugs may alleviate bone-related events and kill tumors localized in bones.
A new study finds that over 50% of small-molecule drug patents this century are connected to NIH-backed research that would likely be cut under a 40% budget reduction. This highlights the significant impact of federally funded research on the development of life-changing medicines.
The NF-κB signaling pathway plays a key role in regulating immune responses, inflammation, cell development, and proliferation. Research into its functions and mechanisms continues to uncover new breakthroughs in immunology and life sciences.
Researchers discovered onnamides, a family of compounds from Okinawan marine sponges, showing remarkable potential against Leishmania major. These compounds demonstrate potency and safety exceeding current treatments, offering new approaches to overcome drug resistance.
The USC team is developing a new drug aimed at a previously unexplored biological target in Alzheimer’s disease, focusing on a trigger of brain inflammation. They have identified an enzyme that predisposes the brain to inflammation and are now working to find a drug that can block it without harmful side effects.
A large international clinical trial found that elinzanetant significantly reduces hot flashes and night sweats in postmenopausal women by over 73%. The drug also shows secondary benefits such as improved quality of life and reduced sleep disturbances, with no harmful effects on the liver or bone density.
Armida Labs will use the funding to advance preclinical studies of Targefrin, a potential clinical candidate for pancreatic and other cancers. The grant aims to develop an anti-metastatic agent that targets the EphA2 protein, which drives cancer cell invasion and metastasis.
A novel method combining biological experiments and information science techniques reveals cancer cells' preference for aerobic glycolysis despite sufficient oxygen availability. This research provides a powerful tool for identifying metabolic vulnerabilities in cancer cells, which could lead to more effective treatments.
The C-Path Translational Therapeutics Accelerator has completed a record year of funding and mentorship, supporting seven projects in 2025 with approximately $2.48 million in awards. The program awarded grants to teams advancing treatments for rare liver disease, drug-resistant lung infections and pediatric brain tumors.
Ibezapolstat, a new antibiotic, has been shown to be effective in treating Clostridioides difficile (C. diff) infections with high rates of sustained clinical cures. The study found that ibezapolstat killed harmful bacteria without harming the good bacteria in the gut, which helps prevent recurrent C. diff infections.
The global market for AI in pharmaceuticals is projected to reach $13.4 billion by 2035, driven by Insilico Medicine's innovative use of generative AI. The company will share its achievements at a satellite forum during BIOHK2025, showcasing significant efficiency boosts compared to traditional methods.
The latest issue of SLAS Technology highlights significant advancements in biomedicine and diagnostics, with AI-powered tools achieving 99.9% accuracy in detecting monkeypox. Additionally, the journal showcases innovative lab technologies, including multi-camera zebrafish assays and infection-proof titanium implants.
Researchers at the University of Pennsylvania used AI to identify previously unknown compounds in Archaea that could fuel the development of next-generation antibiotics. The study, published in Nature Microbiology, found that 93% of the identified archaeasins demonstrated antimicrobial activity against drug-resistant bacteria.
The new book explores organoid bioengineering, using pluripotent and adult stem cells to create models for various organs. It discusses breakthroughs in personalized cancer care and large-scale production protocols supported by advanced tools like 3D printing and genome editing.
The journal features novel FAK-paxillin inhibitors, a venom toxin screening platform, and AI-driven solubility prediction for compound discovery. SLAS Discovery highlights innovative technologies to understand and treat human disease.
Repair Biotechnologies develops therapies targeting toxic excess free cholesterol in cells, a hallmark of aging and obesity. The company is advancing a lead drug for accelerated atherosclerosis, with ARDD providing opportunities to connect with brilliant minds and showcase groundbreaking research.
LongGame Ventures supports cutting-edge research in longevity biotechnology at ARDD 2025, featuring Nobel laureates and industry leaders. The conference aims to advance healthspan and longevity science, with a focus on regenerative medicine and cellular replacement.
The 2025 Critical Path Institute Global Impact Conference will bring together industry, regulatory agencies, academia, and patient advocacy groups to discuss pressing challenges in drug development. The event aims to foster cross-sector collaboration to advance medical innovation and improve treatment outcomes for patients.
The inaugural ESMO Targeted Anticancer Therapies (TAT) Asia Congress 2025 will convene a diverse group of stakeholders to foster collaboration and accelerate the development of innovative cancer therapies. The congress aims to become a catalyst for global collaboration and innovation in oncology.
The Society for Laboratory Automation and Screening's two scientific journals, SLAS Discovery and SLAS Technology, have achieved substantial impact factor increases due to open access publishing. This shift has led to higher citations and visibility for authors, with SLAS Technology experiencing a notable rise of 1.2 points to 3.7.
Scientists have identified compounds that can help cells fend off viral infection by activating the integrated stress response pathway. These compounds show promise as broad-spectrum antivirals against multiple types of viruses and have been tested in human cells and a mouse model with positive results.
Two Bar-Ilan University researchers have won ERC grants to advance cancer treatments using targeted protein degradation and improve regulatory effectiveness through machine learning. The projects aim to pioneer new therapeutics and design more effective interventions based on empirical evidence.
At the upcoming AI for Good Global Summit, Alex Zhavoronkov PhD will discuss the future potential of generative AI. Insilico Medicine's founder and CEO has invented critical technologies in generative AI and reinforcement learning, and his keynote will explore applications in drug discovery and longevity.
A team of researchers proposes a novel adaptive platform trial fund to accelerate ALS drug development. The study outlines a financing model that merges efficiencies with an innovative royalty-based investment structure, drawing on data from the HEALEY ALS Platform Trial. This new approach could transform how diseases like ALS are addr...
Scientists from the University of Bath have identified two new families of chemical compounds that inhibit alpha-methylacyl-CoA racemase (MCR) in Mycobacterium tuberculosis, a key enzyme for TB survival. This breakthrough could lead to new treatments for TB and potentially other diseases like prostate cancer.
Researchers at Florida Atlantic University have secured two key grants to investigate targeting the MBLAC1 gene as a new approach to treat glioblastoma, a very aggressive and fast-growing type of brain cancer. The project aims to advance innovative projects that could make a meaningful impact on cancer therapy.
A new computational tool called ColdBrew predicts the likelihood of water molecule positions within experimental protein structures, aiding drug discovery efforts. The tool leverages data on extensive protein water networks, providing insights into how ligands bind to proteins and potentially improving binding sites.
This issue of SLAS Technology features a high-precision microfluidic flow splitter that outperforms commercial alternatives, enabling even flow division and simplifying multi-inlet perfusion. The journal showcases technological leaps in the life sciences, including rapid pathogen detection and AI-driven insights into schizophrenia.
UVA Health received two anonymous $25 million estate gifts to support the Paul and Diane Manning Institute of Biotechnology. The institute will develop new treatments for hard-to-treat diseases with a state-of-the-art biomedical research facility expected to drive economic growth in Central Virginia.
Researchers tackle pressing challenges in drug discovery with innovative approaches, including high-throughput TRIP13 inhibitors and tau aggregation blockers. The journal focuses on advancing life sciences discovery and technology via education, knowledge exchange and global community building.
Researchers at the University of Pennsylvania School of Engineering and Applied Science have turned a deadly fungus into a potent cancer-fighting compound. The new compound, called asperigimycins, has shown promising results against leukemia cells, rivaling FDA-approved drugs.
Critical Path Institute's Translational Therapeutics Accelerator awards $250,000 to researchers advancing a promising therapeutic pathway for type 1 diabetes. The project aims to address key challenges in T1D treatment, including beta-cell preservation and immune system modulation.